[1] KHATUN M, RAY R B. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis[J]. Cells, 2019, 8(10):1249. doi:  10.3390/cells8101249
[2] TACKE F. Targeting hepatic macrophages to treat liver diseases[J]. Hepatol, 2017, 66(6):1300-1312. doi:  10.1016/j.jhep.2017.02.026
[3] PRADERE J P, KLUWE J, DE MINICIS S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J]. Hepatology, 2013, 58(4):1461-73. doi:  10.1002/hep.26429
[4] LI J, ZHAO Y P, TIAN Z. Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis[J]. World J Hepatol, 2019, 11(5):412-420. doi:  10.4254/wjh.v11.i5.412
[5] WEN Y K, LAMBRECHT J, JU C, et al. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities[J]. Cell Mol Immunol, 2021, 18(1):45-56. doi:  10.1038/s41423-020-00558-8
[6] KIAGIADAKI F, KAMPA M, VOUMVOURAKI A, et al. Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(3):891-899. doi:  10.1016/j.bbadis.2017.12.031
[7] SASAKI R, DEVHARE P B, STEELE R, et al. Hepatitis C virus-induced CCL5 secretion from macrophages activates hepa-tic stellate cells[J]. Hepatology, 2017, 66(3):746-757. doi:  10.1002/hep.29170
[8] NIELSEN S R, QUARANTA V, LINFORD A, et al. Macro-phage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis[J]. Nat Cell Biol, 2016, 18(5):549-560. doi:  10.1038/ncb3340
[9] GE X D, ARRIAZU E, MAGDALENO F, et al. High mobility group box-1 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice[J]. Hepatology, 2018, 68(6):2380-2404. doi:  10.1002/hep.30093
[10] SHIRABE K, BEKKI Y, GANTUMUR D, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis[J]. J Gastroenterol, 2018, 53(7):819-826. doi:  10.1007/s00535-017-1425-z
[11] WANG C, MA C, GONG L H, et al. Macrophage polarization and its role in liver disease[J]. Front Immunol, 2021, 12:803037. doi:  10.3389/fimmu.2021.803037
[12] SINGANAYAGAM A, TRIANTAFYLLOU E. Macrophages in chronic liver failure: diversity, plasticity and therapeutic targeting[J]. Front Immunol, 2021, 12:661182. doi:  10.3389/fimmu.2021.661182
[13] XU J J, ZHU L, LI H D, et al. DNMT3a-mediated methylation of PSTPIP2 enhances inflammation in alcohol-induced liver injury via regulating STAT1 and NF-κB pathway[J]. Pharmacol Res, 2022, 177:106125. doi:  10.1016/j.phrs.2022.106125
[14] SU S B, QIN S Y, XIAN X L, et al. Interleukin-22 regulating Kupffer cell polarization through STAT3/Erk/Akt crosstalk pathways to extenuate liver fibrosis[J]. Life Sci, 2021, 264:118677. doi:  10.1016/j.lfs.2020.118677
[15] TOSELLO-TRAMPONT A C, KRUEGER P, NARAYANAN S, et al. NKp46+ natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice[J]. Hepatology, 2016, 63(3):799-812. doi:  10.1002/hep.28389
[16] CALVENTE C J, TAMEDA M, JOHNSON C D, et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223[J]. J Clin Investig, 2019, 129(10):4091-4109. doi:  10.1172/JCI122258
[17] SHE S P, WU X N, ZHENG D F, et al. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target[J]. J Hepatol, 2020, 72(3):506-518. doi:  10.1016/j.jhep.2019.09.033
[18] SUN H F, FENG J G, TANG L L. Function of TREM1 and TREM2 in liver-related diseases[J]. Cells, 2020, 9(12):2626. doi:  10.3390/cells9122626
[19] KOHYAMA M, MATSUOKA S, SHIDA K, et al. Monocyte infiltration into obese and fibrilized tissues is regulated by PILRα[J]. Eur J Immunol, 2016, 46(5):1214-1223. doi:  10.1002/eji.201545897
[20] RAMACHANDRAN P, DOBIE R, WILSON-KANAMORI J R, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level[J]. Nature, 2019, 575(7783):512-518. doi:  10.1038/s41586-019-1631-3
[21] ZHOU H M, ZHONG W Z, RAO Z, et al. Defective mitophagy in aged macrophages promotes mitochondrial DNA cytosolic leakage to activate STING signaling during liver sterile inflammation [J]. Aging Cell, 2022, 21(6):e13622.
[22] YU Y S, LIU Y, AN W S, et al. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis[J]. J Clin Invest, 2019, 129(2):546-555.
[23] HU Q, LYON C J, FLETCHER J K, et al. Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses[J]. Acta Pharm Sin B, 2021, 11(6):1493-1512. doi:  10.1016/j.apsb.2020.12.014
[24] ROSSO C, KAZANKOV K, YOUNES R, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease[J]. J Hepatol, 2019, 71(5):1012-1021. doi:  10.1016/j.jhep.2019.06.031
[25] LESLIE J, MACIA M G, LULI S, et al. C-rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis[J]. Nat Metab, 2020, 2(11):1350-1367. doi:  10.1038/s42255-020-00306-2
[26] KANAMORI Y, TANAKA M, ITOH M, et al. Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH[J]. iScience, 2021, 24(2):102032. doi:  10.1016/j.isci.2020.102032
[27] XU F, GUO M M, HUANG W, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH[J]. Redox Biol, 2020, 36:101634. doi:  10.1016/j.redox.2020.101634
[28] SUN K, XU L Y, JING Y Y, et al. Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α/β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis[J]. Cancer Lett, 2017, 388:198-207. doi:  10.1016/j.canlet.2016.12.004
[29] CHENG D, CHAI J, WANG H W, et al. Hepatic macrophages: key players in the development and progression of liver fibrosis[J]. Liver Int, 2021, 41(10):2279-2294. doi:  10.1111/liv.14940
[30] ZHU J F, ZHANG W W, ZHANG L N, et al. IL-7 suppresses macrophage autophagy and promotes liver pathology in Schistosoma japonicum-infected mice[J]. J Cell Mol Med, 2018, 22(7):3353-3363. doi:  10.1111/jcmm.13610
[31] WAN J H, WEISS E, BEN MKADDEM S, et al. LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling[J]. Sci Transl Med, 2020, 12(539):eaaw8523. doi:  10.1126/scitranslmed.aaw8523
[32] AN P, WEI L L, ZHAO S S, et al. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis[J]. Nat Commun, 2020, 11:2362. doi:  10.1038/s41467-020-16092-0
[33] LI L A, WEI W, LI Z Z, et al. The spleen promotes the secretion of CCL2 and supports an M1 dominant phenotype in hepatic macrophages during liver fibrosis[J]. Cell Physiol Biochem, 2018, 51(2):557-574. doi:  10.1159/000495276
[34] ZHAO X T, WANG J, DENG Y, et al. Quercetin as a protective agent for liver diseases: a comprehensive descriptive review of the molecular mechanism[J]. Phytother Res, 2021, 35(9):4727-4747. doi:  10.1002/ptr.7104
[35] LIU P, LI H, GONG J S, et al. Chitooligosaccharides alleviate hepatic fibrosis by regulating the polarization of M1 and M2 macrophages[J]. Food Funct, 2022, 13(2):753-768. doi:  10.1039/D1FO03768D
[36] ZHENG Z Q, WANG H A, LI L A, et al. Splenectomy enhances the Ly6Clow phenotype in hepatic macrophages by activating the ERK1/2 pathway during liver fibrosis[J]. Int Immunopharmacol, 2020, 86:106762. doi:  10.1016/j.intimp.2020.106762
[37] ZHAO X G, CHEN G M, LIU Y, et al. Curcumin reduces Ly6Chi monocyte infiltration to protect against liver fibrosis by inhibiting Kupffer cells activation to reduce chemokines secretion[J]. Biomed Pharmacother, 2018, 106:868-878. doi:  10.1016/j.biopha.2018.07.028
[38] AMBADE A, LOWE P, KODYS K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice[J]. Hepatology, 2019, 69(3):1105-1121. doi:  10.1002/hep.30249
[39] AIDA H, DINA C, WAN J H, et al. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver[J]. Gut, 2019, 68(3):522-532. doi:  10.1136/gutjnl-2018-316137
[40] FRIEDMAN S L, RATZIU V, HARRISON S A, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67(5):1754-1767. doi:  10.1002/hep.29477
[41] MORONI F, DWYER B J, GRAHAM C, et al. Safety profile of autologous macrophage therapy for liver cirrhosis[J]. Nat Med, 2019, 25(10):1560-1565. doi:  10.1038/s41591-019-0599-8
[42] WEISKIRCHEN R, TACKE F. Liver fibrosis: from pathogenesis to novel therapies[J]. 2016, Dig Dis, 34(4): 410-422.
[43] LOOMBA R, LAWITZ E, MANTRY P S, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2018, 67(2):549-559. doi:  10.1002/hep.29514
[44] RAMACHANDRAN P, PELLICORO A, VERNON M A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis[J]. Proc Natl Acad Sci U S A. 2012, 109(46): E3186-3195.
[45] KOYAMA Y, BRENNER D A. Liver inflammation and fibrosis[J]. J Clin Invest, 2017, 127(1):55-64. doi:  10.1172/JCI88881
[46] BAECK C, WEI X, BARTENECK M, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice[J]. Hepatology, 2014, 59(3):1060-1072. doi:  10.1002/hep.26783